Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 3, 2009, Pages 571-572

  Caykoylu, Ali ^a   Ekinci, Okan ^a   Yilmaz, Elif ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; RISPERIDONE;

ADULT; CASE REPORT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; MONOTHERAPY; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; PIPERAZINES; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA;

EID: 62849084050     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.01.009     Document Type: Letter

References (15)

1. Akam E., and Strange P.G. Inverse agonist properties of atypical antipsychotic drugs. Biochem Pharmacol 67 (2004) 2039-2045
2. Alcohol Drug Abuse and Mental Health Administration. Abnormal involuntary movement scale (AIMS) (1974), Department of Health, Education and Welfare, Washington, DC
3. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (4th ed., text rev.) (2000), Author, Washington, DC
4. del Miller D., Eudicone J.M., Pikalov A., and Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry 68 12 (2007) 1901-1906
5. Duggal H.S. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry 48 (2003) 771-772
6. Grant M.J., and Baldessarini R.J. Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 39 (2005) 1953
7. Inoue A., Miki S., Seto M., Kikuchi T., Morita S., Ueda H., et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 321 1 (1997) 105-111
8. Kantrowitz J.T., Srihari V.H., and Tek C. Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot. J Clin Psychopharmacol 27 (2007) 525-526
9. Lykouras L., Rizos E., and Gournellis R. Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 1535-1536
10. Mamo D., Graff A., Mizrahi R., Shammi C.M., Romeyer F., and Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164 (2007) 1411-1417
11. Maytal G., Ostacher M., and Stern T.A. Aripiprazole related-tardive dyskinesia. CNS Spectr 11 6 (2006) 435-439
12. Sharma A., Ramaswamy S., and Dewan V.K. Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry 7 (2005) 36
13. Soares-Weiser K., and Fernandez H.H. Tardive dyskinesia. Semin Neurol 27 (2007) 159-169
14. Tamminga C.A., and Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 1 (2002) 141-147
15. Witschy J.K., and Winter A.S. Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatry 50 (2005) 188